388 related articles for article (PubMed ID: 26751109)
1. Emerging drugs for the treatment of mucopolysaccharidoses.
Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
[TBL] [Abstract][Full Text] [Related]
2. Current and potential therapeutic strategies for mucopolysaccharidoses.
Noh H; Lee JI
J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
[TBL] [Abstract][Full Text] [Related]
3. Phase I and II clinical trials for the mucopolysaccharidoses.
Poswar F; Baldo G; Giugliani R
Expert Opin Investig Drugs; 2017 Dec; 26(12):1331-1340. PubMed ID: 29065735
[TBL] [Abstract][Full Text] [Related]
4. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology applied to treatment of mucopolysaccharidoses.
Schuh RS; Baldo G; Teixeira HF
Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
[TBL] [Abstract][Full Text] [Related]
6. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
[TBL] [Abstract][Full Text] [Related]
7. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
Muenzer J
Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
[TBL] [Abstract][Full Text] [Related]
8. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
9. Overview of the mucopolysaccharidoses.
Muenzer J
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v4-12. PubMed ID: 22210669
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
[TBL] [Abstract][Full Text] [Related]
11. Therapies for the bone in mucopolysaccharidoses.
Tomatsu S; Alméciga-Díaz CJ; Montaño AM; Yabe H; Tanaka A; Dung VC; Giugliani R; Kubaski F; Mason RW; Yasuda E; Sawamoto K; Mackenzie W; Suzuki Y; Orii KE; Barrera LA; Sly WS; Orii T
Mol Genet Metab; 2015 Feb; 114(2):94-109. PubMed ID: 25537451
[TBL] [Abstract][Full Text] [Related]
12. Therapy for the mucopolysaccharidoses.
Valayannopoulos V; Wijburg FA
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
[TBL] [Abstract][Full Text] [Related]
13. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
Kakkis E; Marsden D
Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
[TBL] [Abstract][Full Text] [Related]
14. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy: efficacy and limitations.
Concolino D; Deodato F; Parini R
Ital J Pediatr; 2018 Nov; 44(Suppl 2):120. PubMed ID: 30442189
[TBL] [Abstract][Full Text] [Related]
16. Current and new therapies for mucopolysaccharidoses.
Penon-Portmann M; Blair DR; Harmatz P
Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
Lau AA; Hemsley KM
J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
[TBL] [Abstract][Full Text] [Related]
19. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
Nan H; Park C; Maeng S
Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
[No Abstract] [Full Text] [Related]
20. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy.
Fecarotta S; Gasperini S; Parenti G
Ital J Pediatr; 2018 Nov; 44(Suppl 2):124. PubMed ID: 30442204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
